Relapsed and Refractory Blood Cancers: A Guide to Diagnosis and Treatment

Blood cancers are a diverse group of diseases that affect the blood, bone marrow, lymphatic system, or plasma cells. They include leukaemias, lymphomas, and multiple myeloma. Although many patients achieve remission with initial treatment, some cancers may return after a period of improvement or fail to respond adequately to therapy from the beginning.

These types of conditions are referred to as relapsed and refractory diseases, which can make treatment difficult. But advances in targeted therapies, immunotherapy, cellular therapy, antibody therapies, and stem cell transplantation have given patients more treatment options. Most significantly, relapsed and refractory conditions do not constitute just one condition. Certain treatments must account for the specific blood cancer subtype, prior treatments, molecular characteristics, duration of remission, and the patient's overall health.

What Do Relapsed and Refractory Blood Cancer Mean?

A relapsed blood cancer is one that has returned after a patient previously achieved a response or remission. Doctors may detect relapse through blood tests, bone marrow examination, imaging, molecular testing, or new symptoms.

A refractory blood cancer is one that does not respond adequately to treatment or continues to progress despite therapy. Some cancers may be refractory from the outset, while others become resistant after an initial response.

Differentiating these types of cancer is clinically significant, as treatment selection often depends on the cancer's prior response to therapy, the speed of recurrence, and the treatments the patient has previously received.

Relapse vs Refractory Disease

Feature	Relapsed Disease	Refractory Disease
Meaning	Cancer returns after a response or remission	Cancer fails to respond adequately to treatment
Timing	May occur months or years after treatment	May be present during or shortly after treatment
Treatment approach	Often involves a new or previously effective therapy	Usually requires a different strategy or clinical trial
Assessment	Blood, marrow, imaging and/or molecular testing	Response assessment and resistance evaluation
Possible options	Targeted therapy, immunotherapy, transplant, cellular therapy	Salvage therapy, targeted treatment, cellular therapy, transplant or trials

The prognosis varies considerably between different blood cancers. For example, relapsed acute myeloid leukaemia (AML) has different treatment considerations from relapsed diffuse large B-cell lymphoma (DLBCL) or multiple myeloma.

Why Does Blood Cancer Relapse or Become Resistant?

Cancer cells can develop biological changes that allow them to survive treatment. Some cancer cells may already have resistance traits before therapy begins, while others acquire genetic or molecular changes during treatment.

Factors associated with treatment resistance or relapse can include:

Aggressive disease biology
High-risk genetic or molecular abnormalities
Incomplete response to initial treatment
Measurable residual disease after therapy
Short duration of the previous remission
Multiple previous lines of treatment
Changes in cancer-cell targets
Development of drug-specific resistance mechanisms

Modern treatment therefore increasingly involves identifying why the cancer has returned or stopped responding, rather than simply repeating the original treatment.

How Is Relapsed or Refractory Blood Cancer Diagnosed?

Diagnosis usually begins with confirmation that the cancer has returned or remains active. The evaluation may involve several tests.

Blood Tests: A complete blood count can identify abnormalities in red blood cells, white blood cells, and platelets. Blood chemistry tests may also evaluate kidney and liver performance, electrolyte abnormalities, uric acid, lactate dehydrogenase, and other factors that matter in therapy planning.
Bone Marrow Testing: Bone marrow aspiration and biopsy tests are critical in leukemia and plasma cell diseases. Testing may include morphology, flow cytometry, cytogenetics, fluorescence in situ hybridisation (FISH), and molecular testing.
Imaging: Patients with lymphoma receive CT, PET/CT, and other imaging based on pathology and clinical status. Imaging can identify the site of recurrent disease and assess treatment response.
Genetic and Molecular Testing: DNA testing can identify changes or defects in chromosomal structures that may affect treatment protocols.
Measurable Residual Disease Testing: Measurable residual disease (MRD) testing is capable of identifying tiny amounts of cancer cells that are still present following treatment. Depending on the type of cancer, MRD testing can be done by using flow cytometry, molecular technology, and other laboratory techniques that are highly sensitive.

What Are the Major Treatment Options?

Treatment is highly individualised. A specialist may consider whether the objective is to achieve another remission, proceed to transplantation or cellular therapy, control the cancer for as long as possible, or relieve symptoms and maintain quality of life.

Salvage Chemotherapy

Salvage chemotherapy refers to treatment given after previous therapy has failed or the disease has returned. It may reduce the cancer burden and, in selected patients, prepare them for stem cell transplantation. However, repeating the same chemotherapy is not always appropriate. Clinicians must consider prior treatment exposure, toxicity, resistance patterns, and the patient's overall condition.

Targeted Therapy

Targeted medicines interfere with specific molecular pathways or proteins that cancer cells depend on. In CLL, treatment options for recurrent or refractory disease include BTK inhibitors and venetoclax-based approaches. The non-covalent BTK inhibitor pirtobrutinib is also being studied and used in appropriate treatment settings, particularly after previous covalent BTK inhibitor exposure.

Immunotherapy

By enhancing the immune system activity against malignant cells, immunotherapy is effective in treating blood cancer. Some common methods of immunotherapy are the use of CAR T-cell therapy, monoclonal antibodies, and checkpoint inhibitors.

CAR T-Cell Therapy

CAR T-cell therapy is a form of personalised cellular therapy. T cells are collected from the patient, genetically modified in a laboratory to recognise a cancer-associated target, expanded, and subsequently infused back into the patient. CAR T-cell therapy has become an important treatment option for selected relapsed or refractory B-cell malignancies and multiple myeloma.

Bispecific Antibodies

Bispecific antibodies bind two different targets, often bringing a patient's T cells into close contact with cancer cells. In relapsed/refractory large B-cell lymphoma, bispecific antibodies such as epcoritamab and glofitamab are treatment options in appropriate settings.

Stem Cell Transplantation

Allogeneic stem cell transplantation uses blood-forming stem cells from a donor. It can provide a graft-versus-leukaemia or graft-versus-tumour effect and remains an important potentially curative strategy for selected patients with relapsed or refractory disease.

What Are the Important Side Effects of Advanced Treatments?

Treatment	Important Potential Complications
Chemotherapy	Infection, low blood counts, nausea, mucositis, organ toxicity
Targeted therapy	Drug-specific effects, cytopenias, liver abnormalities, cardiac or metabolic effects depending on the agent
CAR T-cell therapy	Cytokine release syndrome, neurological toxicity, prolonged low blood counts, infections
Bispecific antibodies	Cytokine release syndrome, infections, low blood counts and other immune-related effects
Stem cell transplantation	Infection, graft-versus-host disease, organ toxicity, infertility and prolonged immune suppression

What Is the Role of Clinical Trials?

Clinical trials are particularly important for relapsed and refractory blood cancers because resistance to previous therapies can limit conventional options.

Trials may investigate:

New targeted therapies
Upcoming CAR T-cell products
Two binding antibodies
Combination therapies
Innovative techniques for stem cell transplantation
New agents for cancer with a specific molecular configuration
Treatment plans developed to counter resistance

For people whose disease has worsened after many treatments, clinical trials may offer therapies that are not yet commonly used.

The Future of Relapsed and Refractory Blood Cancer Treatment

Molecular profiling, MRD testing, targeted therapies, immune-based treatments, bispecific antibodies, and cellular therapies are increasingly being incorporated into treatment planning.

Studies are also investigating how best to combine and sequence these therapies. Ongoing clinical studies are focusing on new CAR T-cell constructs, bispecific antibodies, combination therapy approaches, and options for patients whose cancer has progressed after previous treatments, including cell- and immune-based therapies.

This means that relapse or treatment resistance does not automatically mean that treatment options have been exhausted. A specialist reassessment can identify whether the disease has a targetable abnormality, whether another line of therapy may be effective, or whether the patient could benefit from transplantation or a clinical trial.

Conclusion

Relapsed and refractory hematological malignancies pose complicated therapeutic difficulties, but innovative methods like targeted treatments, immunotherapy, cell therapy, and stem cell transplantation have led to the emergence of new options. Timely reevaluation, precise disease definition, and specialist consultation are key to choosing the right treatment. Depending on the cancer subtype and other factors, therapy may aim for complete remission, long-term disease control, or improved quality of life.

Reference

Frequently Asked Questions

There is no single answer because outcomes vary considerably between different blood cancer types and individual patients. Some patients may achieve another remission, while selected patients may be candidates for potentially curative treatments such as stem cell transplantation or cellular therapy. In other cases, treatment may focus on long-term disease control and quality of life.

A second opinion can help patients understand their diagnosis and treatment options when disease has relapsed or become refractory. Patients should provide pathology and bone marrow reports, previous treatment records, imaging, molecular and cytogenetic results, MRD results when available, and their medication history. They should also share information about previous transplantation, CAR T-cell therapy, or immunotherapy. The specialist can then reassess the disease and determine whether another treatment, cellular therapy, transplantation, or a clinical trial may be appropriate.

Patients should consider a centre with experienced haematologists and haemato-oncologists and access to advanced diagnostic and treatment facilities. Important services may include molecular testing, flow cytometry, bone marrow evaluation, stem cell transplantation, and CAR T-cell therapy when appropriate. The centre should also have critical-care support, infection-management expertise, blood-bank services, and access to clinical trials. Rehabilitation and supportive-care services can further help manage treatment-related effects.

A second opinion may be particularly useful when the cancer has returned quickly, failed to respond to treatment, or progressed after multiple therapies. It can also help when considering several treatment options, transplantation, CAR T-cell therapy, or clinical trials. A specialist review may confirm the existing treatment plan or identify additional options based on the disease's molecular and clinical characteristics.

Treatment selection depends on the type and stage of blood cancer, previous treatments, duration of remission, molecular characteristics, overall health, and treatment response. Doctors may consider targeted therapy, chemotherapy, immunotherapy, bispecific antibodies, CAR T-cell therapy, stem cell transplantation, or clinical trials.